Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma

Phase II of Lenvatinib Plus Toripalimab for Advanced HCC

NCT03919383 ·Status: WITHDRAWN ·Phase: PHASE2

Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

NCT04168944 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

NCT05010681 ·Status: RECRUITING ·Phase: PHASE2

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

NCT06519721 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

NCT04297254 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

NCT04241523 ·Status: UNKNOWN ·Phase: PHASE2

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT02953743 ·Status: COMPLETED ·Phase: PHASE1

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

NCT03744247 ·Status: WITHDRAWN ·Phase: PHASE3

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

NCT04053972 ·Status: UNKNOWN ·Phase: PHASE3

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03433703 ·Status: TERMINATED ·Phase: PHASE2

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

NCT04443309 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma

NCT05509478 ·Status: UNKNOWN ·Phase: PHASE2

Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma

NCT04527679 ·Status: UNKNOWN ·Phase: PHASE2

Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection

NCT04044651 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

NCT04053985 ·Status: UNKNOWN ·Phase: PHASE3

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

NCT04627012 ·Status: COMPLETED

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

NCT06034977 ·Status: RECRUITING ·Phase: PHASE2

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

NCT06361758 ·Status: WITHDRAWN ·Phase: PHASE2

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

NCT05608213 ·Status: RECRUITING ·Phase: PHASE3

PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial

NCT04814043 ·Status: UNKNOWN ·Phase: PHASE2

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

NCT06315101 ·Status: COMPLETED

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

NCT03791918 ·Status: WITHDRAWN ·Phase: PHASE3

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NCT05444478 ·Status: RECRUITING ·Phase: NA

Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors

NCT04428437 ·Status: TERMINATED

Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma

NCT04227808 ·Status: UNKNOWN ·Phase: PHASE2